This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment. Register Today!
IMG-007-203 – Atopic Dermatitis
This Phase 2a study is the first to evaluate safety and efficacy of a non-depleting OX40 mAb in moderate-to-severe AD patients. The objective is to demonstrate that blocking OX40 without depleting T cells results in good clinical safety and efficacy. Register Today!
M24-885
This Phase 2a proof of concept (PoC) study is a 24-week Induction and Maintenance Period and a 72-week Long-Term Extension Period treat-through design study that utilizes a platform framework. The study will evaluate the clinical efficacy and safety of targeted therapies (TaTs) in moderate to severe CD. For the purpose of this protocol, TaTs represent…